United States Patent 9,937,181: Tofacitinib Extended-Release Patent Scope, Claims, Exclusivity and Generic Risk

U.S. Patent No. 9,937,181 protects once-daily, 11-mg tofacitinib dosage forms that use osmotic delivery through a semipermeable membrane and a water-insoluble cellulose derivative, particularly cellulose acetate. Its claims cover both physical drug-release performance and pharmacokinetic outcomes. The patent is directed to the extended-release formulation marketed as Xeljanz XR, rather than to tofacitinib as a chemical compound.

The strongest infringement risk applies to an 11-mg once-daily product that uses an osmotic core, cellulose-acetate membrane, and release or exposure profile materially matching the claimed ranges. A conventional immediate-release 5-mg twice-daily tofacitinib product is outside the core formulation scope.

What does U.S. Patent 9,937,181 protect?

The patent protects a controlled-release dosage form containing 11 mg of tofacitinib, or an equivalent amount of a pharmaceutically acceptable salt, with four central technical features:

A drug-containing core.
An osmagen in the core.
A semipermeable membrane containing a water-insoluble polymer.
Osmotic delivery as the primary release mechanism.

The claims also require either defined in vitro dissolution characteristics or defined in vivo pharmacokinetic results.

The claim set is directed to dosage forms, not to a method of treating rheumatoid arthritis, psoriasis, ulcerative colitis, or another disease. It also does not claim the tofacitinib molecule itself.

Core claim architecture

Claim group	Principal limitation	Commercial significance
Claim 1	11-mg core, osmagen, semipermeable membrane, water-insoluble cellulose derivative, defined dissolution profile	Direct formulation and release-profile claim
Claims 2-7	Same core architecture plus AUC, Cmax/Cmin and drug-holiday requirements	Pharmacokinetic product claims
Claims 8-16	Exposure per mg, Cmax/Cmin, concentration-above-threshold and Cmax parameters	Alternative pharmacokinetic claim set
Claim 17	Extrudable core, swellable core or asymmetric membrane technology	Captures multiple osmotic delivery designs
Claims 18-23	Cellulose acetate, water-soluble polymer and sorbitol limitations	Narrows the membrane and osmagen composition
Claims 24-25	Low Cmin and fed/fasted exposure limits	Additional performance-based limitations

The independent claims are claims 1, 2 and 8. Claims 3-7 depend from claim 2. Claims 9-16 and 18-25 depend from claim 8, directly or through intervening claims.

How broad are the independent claims?

Claim 1: structural and dissolution protection

Claim 1 requires an 11-mg once-daily sustained-release dosage form with:

A tofacitinib-containing core;
An osmagen;
A semipermeable membrane;
A water-insoluble polymer that is a cellulose derivative;
Primary osmotic delivery; and
A specified dissolution profile.

The dissolution limits are:

Time point	Required dissolution
1 hour	Not more than 30%
2.5 hours	35% to 75%
5 hours	At least 75%

The testing conditions are narrowly defined: 900 mL of 0.05 M pH 6.8 potassium phosphate buffer, 37°C, USP rotating paddle apparatus and 50 rpm.

This is a meaningful limitation. A product may use the same active ingredient and dose but avoid literal infringement of claim 1 if it lacks an osmotic delivery mechanism, uses a non-cellulosic water-insoluble membrane polymer, or falls outside the stated dissolution profile.

The claim is not limited to cellulose acetate. Any water-insoluble cellulose derivative that sustains release may satisfy the claim, subject to the other elements.

Claims 2-7: pharmacokinetic equivalence and fluctuation

Claim 2 protects a formulation that produces an AUC equivalent to the exposure from 5 mg of immediate-release tofacitinib administered twice daily. The claimed AUC range is 80% to 125% of the comparator exposure.

It also requires a geometric mean plasma Cmax-to-Cmin ratio of approximately 10 to 100. Dependent claims narrow that ratio:

Claim	Cmax/Cmin range
Claim 2	About 10 to 100
Claim 3	About 20 to 40
Claim 4	About 20 to 30

Claim 5 adds a mean Cmax range of 70% to 125% relative to the immediate-release twice-daily formulation at steady state. Claims 6 and 7 address the drug holiday, defined as the period during which drug concentrations are below the relevant threshold over a 24-hour interval. Claim 7 narrows the drug holiday to approximately 15 to 18 hours.

These claims are important because they can reach a product even when the exact dissolution profile differs from claim 1. A competing product with substantially similar pharmacokinetics may face risk under claims 2-7 if it also uses the required osmotic and membrane architecture.

Claims 8-16: alternative pharmacokinetic coverage

Claim 8 requires a mean AUC of approximately 17 to 42 ng-hr/mL per mg dosed, together with a Cmax/Cmin ratio of about 10 to 100. Claims 9 and 10 narrow the ratio to 20-40 and 20-30.

Claims 11-15 define the time spent above or below approximately 17 ng/mL:

Claim	Time above 17 ng/mL	Time below 17 ng/mL
Claim 11	6 to 15 hours	9 to 18 hours
Claim 12	6 to 9 hours	Not further narrowed
Claim 13	Not further narrowed	15 to 18 hours
Claim 14	11 to 15 hours	Not further narrowed
Claim 15	Not further narrowed	9 to 13 hours

Claim 16 requires a mean maximum plasma concentration of approximately 3 to 6 ng/mL per mg dosed.

Claims 8-16 are technically demanding because they combine formulation structure with clinical or pharmacokinetic performance. They are not pure result claims. A product must satisfy the structural limitations and the claimed pharmacokinetic result.

What formulations are protected by U.S. Patent 9,937,181?

The dependent claims identify a preferred formulation platform.

Membrane polymer

Claim 18 expressly identifies cellulose acetate. The broader claims cover a water-insoluble cellulose derivative. Potentially relevant cellulose derivatives include cellulose acetate and related esterified cellulose materials, but the specific polymer must satisfy the claim construction applied by a court.

Water-soluble pore former

Claims 19-21 cover a water-soluble polymer in the membrane with an average molecular weight between 2,000 and 100,000 daltons. Claim 20 lists:

Water-soluble cellulose derivatives;
Acacia;
Dextrin;
Guar gum;
Maltodextrin;
Sodium alginate;
Starch;
Polyacrylates; and
Polyvinyl alcohols.

Claim 21 specifically identifies hydroxypropylcellulose, hydroxypropylmethylcellulose and hydroxyethylcellulose.

The pore-former limitations may become important in an ANDA litigation case. A generic developer may avoid claims 19-21 by omitting the listed water-soluble polymer, selecting a different molecular-weight range, or using a different membrane composition. That design-around would not necessarily avoid claims 1, 2 or 8.

Osmagen

Claims 22 and 23 identify sugar as the osmagen and sorbitol as a narrower example. The independent claims require an osmagen but do not require sorbitol. A formulation using another osmotic agent could remain within the independent claims if all other limitations are met.

Osmotic delivery systems

Claim 17 covers three delivery approaches:

Extrudable core systems;
Swellable core systems; and
Asymmetric membrane technology.

This creates alternative coverage for different osmotic tablet designs. Avoiding one delivery architecture does not automatically avoid the claim if another listed system is used.

When does tofacitinib extended-release exclusivity expire?

U.S. Patent No. 9,937,181 was issued on March 20, 2018. The patent is associated with Pfizer’s controlled-release tofacitinib formulation program and covers the dosage form corresponding to Xeljanz XR. Its nominal patent term extends into 2034, subject to the expiration date recorded by the U.S. Patent and Trademark Office and any applicable patent-term adjustment or extension.[1]

The FDA-approved Xeljanz XR product contains 11 mg of tofacitinib and is administered once daily. Immediate-release Xeljanz is generally dosed twice daily at 5 mg for the labeled rheumatoid arthritis regimen, while Xeljanz XR provides the once-daily extended-release alternative.[2]

Exclusivity timeline

Event	Date or period
Tofacitinib first approved in the United States	2012
Xeljanz XR approval	2016
U.S. Patent No. 9,937,181 issued	March 20, 2018
Nominal patent protection	Into 2034
Earliest practical generic risk	Dependent on Orange Book listing, ANDA certification and litigation outcome
Biosimilar pathway	Not applicable because tofacitinib is a small molecule

Patent expiration does not by itself establish the first date on which a generic can launch. An ANDA applicant may challenge the patent before expiration through a Paragraph IV certification. A settlement may permit an earlier authorized or licensed entry date.

What is the Orange Book status of U.S. Patent 9,937,181?

The patent is relevant to the Xeljanz XR 11-mg extended-release product and should be evaluated through the FDA Orange Book patent listing and use-code records.[3] The claim text alone does not establish the current listing status, use code, delisting history, or whether a particular patent is listed against the reference product or a specific dosage form.

The legal significance of an Orange Book listing is substantial:

A Paragraph IV certification can trigger a patent-infringement action under the Hatch-Waxman Act.
A timely action by the reference-product sponsor can create a 30-month stay of FDA approval, subject to statutory exceptions.
A non-Paragraph-IV certification may defer approval until the listed patent expires.
The listing does not determine ultimate validity or infringement.

For this patent, the likely Orange Book relevance is the extended-release 11-mg tablet rather than the immediate-release 5-mg tablet. The claims do not cover every tofacitinib product.

What generic entry risks exist for Xeljanz XR?

A generic 11-mg once-daily product faces the highest risk when its proposed formulation has the following characteristics:

Risk factor	Relevance to Patent 9,937,181
11 mg tofacitinib	Matches the express dose limitation
Once-daily administration	Required by the independent claims
Osmotic core	Matches the primary delivery mechanism
Semipermeable membrane	Required by the independent claims
Cellulose acetate or another insoluble cellulose derivative	Matches the membrane limitation
Sorbitol or another osmagen	Supports the core limitation
Similar dissolution profile	Creates claim 1 risk
Similar AUC and Cmax/Cmin profile	Creates claims 2 and 8 risk
Similar fed/fasted performance	Creates claim 25 risk

A generic that uses a hydrophilic matrix tablet, a non-osmotic multiparticulate system, or a different release mechanism may have a stronger design-around position. It could still face claims 2 or 8 if the patent holder argues that the product satisfies the structural limitations and achieves the claimed pharmacokinetic ranges.

Paragraph IV exposure

A Paragraph IV applicant would likely challenge one or more of:

Written description;
Enablement;
Obviousness;
Definiteness of pharmacokinetic terms;
Infringement based on the applicant’s formulation and ANDA specifications;
The relationship between in vitro dissolution and in vivo pharmacokinetic limitations.

The most vulnerable claim elements may be the broad functional and pharmacokinetic ranges. The most defensible elements may be the combination of a specific 11-mg dose, osmotic delivery, semipermeable membrane and insoluble cellulose derivative.

The patent holder would likely rely on formulation data, dissolution testing, ANDA product information and bioequivalence results to establish infringement.

How strong is the patent estate for tofacitinib extended release?

Patent 9,937,181 has a focused but commercially relevant scope. Its strength comes from claim redundancy rather than broad chemical coverage.

Strengths

Three independent claim pathways address dissolution or pharmacokinetic performance.
The claims cover multiple osmotic technologies.
The claims include both broad and narrow cellulose-derivative limitations.
The 11-mg once-daily dose maps directly onto the commercial extended-release product.
Claims 2 and 8 may capture products with different in vitro release profiles but similar clinical exposure.

Weaknesses

Every independent claim requires osmotic delivery.
Every independent claim requires a water-insoluble cellulose derivative.
The claims are limited to an 11-mg dosage form.
Pharmacokinetic ranges may create claim-construction and reproducibility disputes.
The claimed thresholds depend on testing conditions, patient populations and study design.
The claims do not cover non-osmotic extended-release tofacitinib systems merely because they provide once-daily dosing.

The patent is stronger against a close copy of Xeljanz XR than against a genuinely different extended-release platform.

What patent litigation affects Xeljanz XR?

The supplied claim set does not establish a specific Paragraph IV filing, complaint, settlement agreement or current litigation posture. Patent litigation involving a generic applicant must be assessed from the relevant district-court docket, ANDA notice, FDA listing and settlement documents. The patent number alone does not establish that a particular company has challenged it.

Which companies are challenging Xeljanz XR?

No challenger can be identified from the claim text. Generic companies that develop tofacitinib extended-release products may target the patent through a Paragraph IV certification, but a commercial development program is not evidence of an actual legal challenge.

A complete litigation assessment would distinguish among:

A Paragraph IV notice;
A filed patent-infringement complaint;
A declaratory-judgment action;
A patent settlement;
An authorized-generic agreement; and
A commercial launch after a final court judgment or settlement date.

Are there biosimilar risks for tofacitinib?

There is no biosimilar pathway for tofacitinib. Tofacitinib is a chemically synthesized small-molecule drug, so competitive entry proceeds through the ANDA generic pathway rather than the Biologics Price Competition and Innovation Act pathway.[4]

The relevant competitive risks are:

Generic immediate-release tofacitinib;
Generic extended-release 11-mg tofacitinib;
Alternative modified-release products;
Authorized-generic supply arrangements; and
Therapeutic substitution by other JAK inhibitors.

A generic immediate-release product may compete with Xeljanz XR clinically but would not necessarily infringe Patent 9,937,181.

How does Xeljanz XR compare with immediate-release Xeljanz?

Attribute	Xeljanz immediate release	Xeljanz XR
Active ingredient	Tofacitinib	Tofacitinib
Typical tablet strength relevant to RA	5 mg	11 mg
Dosing frequency	Twice daily	Once daily
Release mechanism	Immediate release	Sustained release, osmotic delivery
Patent 9,937,181 relevance	Generally limited	Core target
Generic pathway	ANDA	ANDA with formulation-patent risk
Biosimilar pathway	Not applicable	Not applicable

The patent is designed to maintain differentiation for once-daily delivery while matching overall exposure to the immediate-release twice-daily regimen.

What revenue exposure does the patent create?

The principal commercial exposure is the loss of once-daily extended-release franchise protection before the patent’s nominal 2034 term. Entry by a generic 11-mg extended-release product could cause:

Price erosion in the XR segment;
Conversion of XR patients to lower-cost generic products;
Rebate pressure on the branded product;
Reduced differentiation from immediate-release generic tofacitinib; and
Potential substitution across JAK inhibitor products.

Revenue analysis requires product-specific sales, geographic mix, patent listing data and actual launch timing. Patent 9,937,181 alone does not establish the value of Xeljanz XR revenue or the percentage of total tofacitinib sales exposed to an adverse validity or infringement outcome.

What geographic coverage does Patent 9,937,181 provide?

U.S. Patent 9,937,181 provides rights only in the United States. Corresponding international applications or foreign national patents may exist, but U.S. claims cannot block manufacture, sale or importation in another jurisdiction unless separate local rights apply.

For a global launch assessment, the relevant questions are:

Whether corresponding patents were granted in Europe, Canada, Japan and other major markets;
Whether those patents have the same claim scope;
Whether local patent-term adjustments apply;
Whether pediatric or regulatory extensions exist; and
Whether local litigation or settlement agreements impose launch restrictions.

The U.S. patent does not itself create worldwide exclusivity.

Key Takeaways

U.S. Patent 9,937,181 is a formulation patent for once-daily, 11-mg extended-release tofacitinib.
Its core combination is an osmagen-containing core, semipermeable membrane, water-insoluble cellulose derivative and primary osmotic delivery.
Claim 1 relies on a defined dissolution profile.
Claims 2-16 add pharmacokinetic coverage, including AUC, Cmax/Cmin, drug holiday and concentration-duration parameters.
Claims 18-23 narrow the formulation to cellulose acetate, water-soluble polymers and sorbitol.
The patent is directed to Xeljanz XR-type products, not to tofacitinib generally.
Nominal patent protection extends into 2034, subject to the official term calculation.
Generic risk is highest for an osmotic 11-mg once-daily tablet using a cellulose-acetate membrane.
Biosimilar risk does not apply; any challenge would proceed through the ANDA and Paragraph IV framework.
A non-osmotic or non-cellulosic extended-release design may provide a stronger design-around position.
Patent litigation, settlement and current Orange Book status cannot be inferred from the claim text alone.

Frequently Asked Questions

Does Patent 9,937,181 cover 5-mg immediate-release tofacitinib?

No. The independent claims require a dosage form comprising 11 mg of tofacitinib or an equivalent salt amount. A conventional 5-mg immediate-release product does not satisfy that dose and formulation combination.

Can a generic avoid the patent by using a different osmagen?

Potentially. Claims 22 and 23 specifically narrow the osmagen to sugar and sorbitol, but claims 1, 2 and 8 require an osmagen without limiting it to sorbitol. Changing the osmagen alone may not avoid the independent claims.

Does cellulose acetate automatically create infringement?

No. Cellulose acetate satisfies one important membrane limitation, but infringement also requires the claimed dose, osmotic architecture, semipermeable membrane and applicable dissolution or pharmacokinetic limitations.

Can a matrix tablet infringe Patent 9,937,181?

A non-osmotic matrix tablet has a stronger design-around position because the independent claims require primary delivery by osmotic pressure. The complete formulation and performance profile would determine the infringement analysis.

Is an ANDA applicant required to wait until 2034 to launch?

Not necessarily. An applicant may challenge the patent through Paragraph IV certification, obtain approval after a successful challenge, launch under a settlement agreement, or enter after patent expiration. The actual launch date depends on litigation, FDA approval and any settlement terms.

References

United States Patent and Trademark Office. (2018). U.S. Patent No. 9,937,181, controlled release formulations of tofacitinib.
U.S. Food and Drug Administration. (2023). Xeljanz and Xeljanz XR prescribing information. Pfizer Laboratories.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2024). Generic drugs and the abbreviated new drug application process.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No	9,937,181*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095487	⤷ Start Trial
Australia	2014233850	⤷ Start Trial
Australia	2017203334	⤷ Start Trial
Brazil	112015020453	⤷ Start Trial
Canada	2905604	⤷ Start Trial
Canada	3037328	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,937,181

Which drugs does patent 9,937,181 protect, and when does it expire?

Summary for Patent: 9,937,181